Recognized as the 2022 Top Emerging Company at the BIO International Convention's Start-Up Stadium, SiVEC Biotechnologies has developed BactPac™, a live biotherapeutic delivery platform to enable the next generation of nucleic acid and gene editing therapies. SiVEC’s BactPac platform is engineered to produce and safely deliver large and structured therapeutic payloads (mRNA, siRNA, proteins/nanobodies, and CRISPR/Cas) to a wide range of targeted tissues that cannot be targeted by viral vectors, lipid nanoparticles, exosomes and other delivery systems. SiVEC’s mission is to use BactPac to develop first-in-class therapeutics targeting cancer, respiratory, and genetic diseases and out-license the BactPac to companies who need a safe, tissue-targeted method of delivery to advance nucleic acid and gene therapies into clinical stages.